Synapse - Works

Results (988)

Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3

Meeting Abstract

Raje, N. S.; Leleu, X. P.; Lesokhin, A. M.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM)

Meeting Abstract

Manasanch, E. E.; Korde, N.; Lee, H. C.; Patel, K. K.; Becnel, M.; Berrios, D.; Thomas, S. K.; Iyer, S. P.; Mailankody, S.; Amini, B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

Meeting Abstract

Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study

Meeting Abstract

Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant

Meeting Abstract

Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma

Meeting Abstract

Lin, Y.; Martin, T. G.; Usmani, S. Z.; Berdeja, J. G.; Jakubowiak, A. J.; Agha, M. E.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies

Meeting Abstract

Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky Yanovsky, A.; Leleu, X. P.; Karlin, L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Lenalidomide-associated B-cell ALL: Clinical and pathologic correlates and sensitivity to lenalidomide withdrawal

Journal Article

Geyer, M. B.; Shaffer, B. C.; Bhatnagar, B.; Mims, A. S.; Klein, V.; Dilip, D.; Glass, J. L.; Lozanski, G.; Hassoun, H.; Landau, H.; more...
Blood Advances (2023)

Fulltext@MSK | Save

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Journal Article

Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
Blood Cancer Journal (2023)

Fulltext@MSK | Save

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel

Review

Raje, N.; Anderson, K.; Einsele, H.; Efebera, Y.; Gay, F.; Hammond, S. P.; Lesokhin, A. M.; Lonial, S.; Ludwig, H.; Moreau, P.; more...
Blood Cancer Journal (2023)

Fulltext@MSK | Save